Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line

Gynecologic Oncology
Ruan Fei, Liu Shaoyang

Abstract

Antigene therapy targeting only one oncogene in ovarian cancer has made much progress, although it still has some limitations. To explore the potential for combination antigene therapy in ovarian cancer, we examined the in vitro effects of liposmal antisense phosphorothioate oligodeoxynucleotides targeting c-erbB(2) and c-myc (LF-c-erbB(2)/c-myc AS-ODNs) in the human ovarian cancer COC(1) cell line. COC(1) cells were treated differently as follows: group A with single LF-c-erbB(2) AS-ODNs; group B with single LF-c-myc AS-ODNs; group C with combination LF-c-erbB(2)/c-myc AS-ODNs; and group D as untreated control. Cell proliferation was studied by MTT assay and clonal cultures. RT-PCR was used to measure gene expression of c-erbB(2) and c-myc before and after transfection. Morphologic changes in the COC(1) cells were observed with the electron microscope. Single antigene therapy targeting c-erbB(2) or c-myc could reduce target gene expression and inhibit COC(1) cell growth by 61.9 +/- 9.3 and 64.5 +/- 11.2%, respectively. However, combination antigene therapy could not only suppress expression of c-erbB(2) and c-myc simultaneously, but also inhibit COC(1) cell proliferation with a higher inhibitory rate of 82.6 +/- 12.1%. Apart f...Continue Reading

References

Nov 27, 1992·Science·J C HanveyK G Au
May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Sep 1, 1990·Gynecologic Oncology·V V BakerD Miller
Oct 1, 1995·Gynecologic Oncology·M F JanicekH E Averette
Jan 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A G van der ZeeE G de Vries
Jan 3, 1997·Biochemical and Biophysical Research Communications·K F PirolloE H Chang
Feb 1, 1997·Gynecologic Oncology·J Boyd, S C Rubin
Mar 18, 1999·Hematology/oncology Clinics of North America·X W TongS M Freeman
Mar 27, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y TsurutaS Fujii

❮ Previous
Next ❯

Citations

Jun 4, 2010·Stem Cell Reviews and Reports·Seung U Kim
Feb 7, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I DimovaD Toncheva
Sep 10, 2003·Hematology/oncology Clinics of North America·Tyler O KirbyRonald D Alvarez
Mar 16, 2021·Frontiers in Oncology·Jeyshka M Reyes-González, Pablo E Vivas-Mejía

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.